Last 12 months
Inside the activity.
0 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2019 Filed Jan 11, 2019 16:10 UTC |
Dillione JanetDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000378 · section16.xml · derivative · entry 3 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-10 F2 · derivative.exercise_date: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:10 UTC |
Dillione JanetDirector
|
GrantRestricted Stock Units | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000378 · section16.xml · nonDerivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,909 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:10 UTC |
Dillione JanetDirector
|
GrantRestricted Stock Units | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000378 · section16.xml · nonDerivative · entry 1 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,909 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:13 UTC |
Gelbfish Gary A.Director
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000380 · section16.xml · derivative · entry 3 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-10 F3 · derivative.exercise_date: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:13 UTC |
Gelbfish Gary A.Director
|
GrantRestricted Stock Units | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000380 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,654,871 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:24 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 120,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000387 · section16.xml · derivative · entry 2 Masson Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:21 UTC |
ARMSTRONG JR. JOHN L.Exec VP of Tech Operations
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 45,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000385 · section16.xml · derivative · entry 2 ARMSTRONG JR. JOHN L. · CIK 0001268675 · Exec VP of Tech Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:17 UTC |
Lefkowitz Steven WDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000383 · section16.xml · derivative · entry 6 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-10 F4 · derivative.exercise_date: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:17 UTC |
Lefkowitz Steven WDirector
|
GrantRestricted Stock Units | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000383 · section16.xml · nonDerivative · entry 3 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,379 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. F2 · ownership.direct: Includes 24,963 shares held by the reporting person for the benefit of his minor son. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:17 UTC |
Lefkowitz Steven WDirector
|
GrantRestricted Stock Units | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000383 · section16.xml · nonDerivative · entry 2 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,379 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. F2 · ownership.direct: Includes 24,963 shares held by the reporting person for the benefit of his minor son. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:17 UTC |
Lefkowitz Steven WDirector
|
GrantRestricted Stock Units | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000383 · section16.xml · nonDerivative · entry 1 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,879 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. F2 · ownership.direct: Includes 24,963 shares held by the reporting person for the benefit of his minor son. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:19 UTC |
Cook Robert W.Chief Financial Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000384 · section16.xml · derivative · entry 2 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:16 UTC |
Khan MehmoodDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000382 · section16.xml · derivative · entry 3 Khan Mehmood · CIK 0001505888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-10 F2 · derivative.exercise_date: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:16 UTC |
Khan MehmoodDirector
|
GrantRestricted Stock Units | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000382 · section16.xml · nonDerivative · entry 2 Khan Mehmood · CIK 0001505888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,083 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:16 UTC |
Khan MehmoodDirector
|
GrantRestricted Stock Units | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000382 · section16.xml · nonDerivative · entry 1 Khan Mehmood · CIK 0001505888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,083 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:02 UTC |
ARMSTRONG JR. JOHN L.Exec VP of Tech Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 18,029 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-000079 · section16.xml · derivative · entry 2 ARMSTRONG JR. JOHN L. · CIK 0001268675 · Exec VP of Tech Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,029 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested 50% on December 31, 2017 and December 31, 2018, subject to continued employment. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:02 UTC |
ARMSTRONG JR. JOHN L.Exec VP of Tech Operations
|
Exercise / conversionCommon Stock | 18,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-000079 · section16.xml · nonDerivative · entry 1 ARMSTRONG JR. JOHN L. · CIK 0001268675 · Exec VP of Tech Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested 50% on December 31, 2017 and December 31, 2018, subject to continued employment. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:19 UTC |
Lefkowitz Steven WDirector
|
PurchaseCommon Stock, $0.001 par value per share | 20,000 | $1.18 | $23,500.00 |
DisclosureSEC source: 0001654954-18-014242 · section16.xml · nonDerivative · entry 1 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wade Capital Corporation Money Purchase Plan Disclosed balance after: 135,757 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.15 to a high of $1.20 per share. F2 · ownership.direct: The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control). Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:16 UTC |
Khan MehmoodDirector
|
PurchaseCommon Stock | 100,000 | $1.24 | $124,410.00 |
DisclosureSEC source: 0001654954-18-014238 · section16.xml · nonDerivative · entry 1 Khan Mehmood · CIK 0001505888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,583 Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 16:01 UTC |
Kaplan MyronDirector
|
PurchaseCommon Stock | 50,000 | $1.47 | $73,300.00 |
DisclosureSEC source: 0001654954-18-014003 · section16.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,166 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.4350 to a high of $1.47 per share. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 21:19 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 40,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001654954-18-013655 · section16.xml · derivative · entry 2 Masson Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vest as follows: 186,000 will vest over four years in four (4) equal installments on the first four anniversaries of 3/19/2018. The remaining options vest on the achievement of certain milestones, subject to continued employment. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 21:19 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
Exercise / conversionCommon Stock | 40,000 | $0.29 | $11,600.00 |
DisclosureSEC source: 0001654954-18-013655 · section16.xml · nonDerivative · entry 1 Masson Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 21:04 UTC |
ARMSTRONG JR. JOHN L.Exec VP of Tech Operations
|
PurchaseCommon Stock | 250,000 | $1.45 | $363,150.00 |
DisclosureSEC source: 0001654954-18-013406 · section16.xml · nonDerivative · entry 1 ARMSTRONG JR. JOHN L. · CIK 0001268675 · Exec VP of Tech Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,861 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.4150 to a high of $1.47. Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 21:55 UTC |
Baluch KhosoDirector · Chief Executive Officer
|
PurchaseCommon Stock | 21,500 | $1.21 | $26,015.00 |
DisclosureSEC source: 0001654954-18-013261 · section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,373 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.21 to a high of $1.22 per share. Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 21:53 UTC |
Cook Robert W.Chief Financial Officer
|
PurchaseCommon Stock | 25,000 | $1.17 | $29,212.50 |
DisclosureSEC source: 0001654954-18-013260 · section16.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,083 Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:55 UTC |
Baluch KhosoDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,500 | $1.28 | $4,480.00 |
DisclosureSEC source: 0001654954-18-013261 · section16.xml · nonDerivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,873 Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 16:19 UTC |
Kaplan MyronDirector
|
PurchaseCommon Stock | 50,000 | $1.30 | $64,795.00 |
DisclosureSEC source: 0001654954-18-013254 · section16.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,166 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.2775 to a high of $1.30 per share. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:07 UTC |
Dillione JanetDirector
|
GrantPhantom Stock · Derivative | 6,637 | $1.13 Strike: $0.00 | $7,499.81 |
DisclosureSEC source: 0001654954-18-012892 · section16.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,637 Underlying: Common Stock · 6,637 shares Expires not disclosed F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. Read SEC document |
| November 14, 2018 Filed Nov 30, 2018 16:21 UTC Amendment |
Dillione JanetDirector
|
GrantPhantom Stock · Derivative | 6,637 | $1.13 Strike: $0.00 | $7,499.81 |
DisclosureSEC source: 0001654954-18-013416 · section16.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,637 Underlying: Common Stock · 6,637 shares Expires not disclosed F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. Read SEC document |
| November 06, 2018 Filed Nov 27, 2018 16:08 UTC |
Kaplan MyronDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-013249 · section16.xml · derivative · entry 2 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These Restricted Stock Units were granted on 11/6/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was November 6, 2018. F1 · derivative.expiration_date: These Restricted Stock Units were granted on 11/6/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was November 6, 2018. Read SEC document |
| November 06, 2018 Filed Nov 27, 2018 16:08 UTC |
Kaplan MyronDirector
|
Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-013249 · section16.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These Restricted Stock Units were granted on 11/6/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was November 6, 2018. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC |
Gelbfish Gary A.Director
|
Exercise / conversionSeries B Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · derivative · entry 4 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F2 · derivative.exercise_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F2 · derivative.expiration_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC |
Gelbfish Gary A.Director
|
Tax withholdingCommon Stock | 468,750 | $2.24 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · nonDerivative · entry 2 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632,371 Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC |
Gelbfish Gary A.Director
|
Exercise / conversionCommon Stock | 1,000,000 | $1.05 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment |
Gelbfish Gary A.Director
|
Exercise / conversionSeries B Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · derivative · entry 4 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F3 · derivative.exercise_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F3 · derivative.expiration_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment |
Gelbfish Gary A.Director
|
Tax withholdingCommon Stock | 468,750 | $2.24 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · nonDerivative · entry 2 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,642,371 F1 · balance_after: This amendment is being filed solely to correct the reporting person's holdings to reflect an ownership correction to a report filed on 2/20/2018 and amended the same date as this amended report. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment |
Gelbfish Gary A.Director
|
Exercise / conversionCommon Stock | 1,000,000 | $1.05 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,111,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amendment is being filed solely to correct the reporting person's holdings to reflect an ownership correction to a report filed on 2/20/2018 and amended the same date as this amended report. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 16:02 UTC |
Kaplan MyronDirector
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010714 · section16.xml · derivative · entry 2 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_date: These restricted stock units were granted on 10/01/2018 for service on the Company's Strategic Finance Committee. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board. F1 · derivative.expiration_date: These restricted stock units were granted on 10/01/2018 for service on the Company's Strategic Finance Committee. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 20:01 UTC |
Lefkowitz Steven WDirector
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010713 · section16.xml · derivative · entry 4 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F3 · derivative.exercise_date: These restricted stock units were granted on 10/01/2018 for service on the Company's Strategic Finance Committee. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board. F3 · derivative.expiration_date: These restricted stock units were granted on 10/01/2018 for service on the Company's Strategic Finance Committee. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| October 01, 2018 Filed Nov 27, 2018 16:09 UTC Amendment |
Kaplan MyronDirector
|
GrantRestricted Stock Units | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-013250 · section16.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,166 F1 · price: These shares consist of restricted stock units granted on 10/1/2018. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board. This amendment reports the restricted stock units in Table I rather than Table II as originally reported. Read SEC document |
| October 01, 2018 Filed Nov 30, 2018 21:14 UTC Amendment |
Lefkowitz Steven WDirector
|
GrantCommon Stock, $0.001 par value per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-013411 · section16.xml · nonDerivative · entry 1 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,379 F1 · price: These shares consist of restricted stock units granted on 10/01/2018. These restricted stock units vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. This amendment reports the restricted stock units in Table I rather than Table II as originally reported. F2 · ownership.direct: Includes 24,963 shares held by the reporting person for the benefit of his minor son. Read SEC document |
| September 10, 2018 Filed Oct 16, 2018 17:07 UTC |
Gelbfish Gary A.Director
|
OtherSeries A Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · derivative · entry 5 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed F3 · security: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. F3 · derivative.exercise_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. F3 · derivative.expiration_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. Read SEC document |
| September 10, 2018 Filed Nov 30, 2018 16:12 UTC Amendment |
Gelbfish Gary A.Director
|
OtherSeries A Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · derivative · entry 5 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed F4 · security: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. F4 · derivative.exercise_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. F4 · derivative.expiration_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 16:01 UTC |
Dillione JanetDirector
|
GrantPhantom Stock · Derivative | 13,636 | $0.55 Strike: $0.00 | $7,499.80 |
DisclosureSEC source: 0001654954-18-009262 · section16.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,636 Underlying: Common Stock · 13,636 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:01 UTC |
Dillione JanetDirector
|
GrantPhantom Stock · Derivative | 37,500 | $0.20 Strike: $0.00 | $7,500.00 |
DisclosureSEC source: 0001654954-18-005595 · section16.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. Read SEC document |
| March 19, 2018 Filed Apr 9, 2018 20:01 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 310,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001654954-18-003745 · section16.xml · derivative · entry 1 Masson Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2028-03-19 F1 · derivative.exercise_date: The options vest as follows: 186,000 will vest over four years in four (4) equal installments on the first four anniversaries of 3/19/2018. The remaining 124,000 options vest on the achievement of certain milestones, subject to continued employment. Read SEC document |
| February 21, 2018 Filed Mar 22, 2018 16:03 UTC |
Kaplan MyronDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-002935 · section16.xml · derivative · entry 2 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was February 21, 2018. F1 · derivative.expiration_date: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was February 21, 2018. Read SEC document |
| February 21, 2018 Filed Mar 22, 2018 16:03 UTC |
Kaplan MyronDirector
|
Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-002935 · section16.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vested in full on the first anniversary of the date of grant, which was February 21, 2018. Read SEC document |
| February 21, 2018 Filed Mar 22, 2018 16:01 UTC |
Dillione JanetDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 15,357 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-002932 · section16.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,357 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vested in full on the first anniversary of the date of grant, which was February 21, 2018. F1 · derivative.expiration_date: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vested in full on the first anniversary of the date of grant, which was February 21, 2018. Read SEC document |
| February 21, 2018 Filed Mar 22, 2018 16:01 UTC |
Dillione JanetDirector
|
Exercise / conversionCommon Stock | 15,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-002932 · section16.xml · nonDerivative · entry 1 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vested in full on the first anniversary of the date of grant, which was February 21, 2018. F1 · price: These Restricted Stock Units were granted on 2/21/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vested in full on the first anniversary of the date of grant, which was February 21, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.